Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Tema Oncology ETF (CANC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) belong to the same industry segment: Tomorrow's Treatments. Both ETFs have the same top 3 sector exposures: and Health Care. CANC is more expensive with a Total Expense Ratio (TER) of 0.99%, versus 0.79% for BBC. CANC is up 4.1% year-to-date (YTD) with +$41M in YTD flows. BBC performs better with 11.12% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of CANC and BBC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CANC BBC | -0.94%+5.80% | +4.18%+9.44% | +4.10%+11.12% | +43.76%+121.56% | n/a+90.43% | n/a-21.96% |
| Flows | CANC BBC | +$12M+$2M | +$49M+$6M | +$41M+$2M | +$63M+$17M | -+$11M | --$2M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CANC BBC | +23.29%+34.38% | +25.13%+39.86% | n/a+36.22% | n/a+39.36% |
| Max drawdown | CANC BBC | -4.68%-11.00% | -17.26%-30.12% | n/a-54.25% | n/a-74.98% |
| Max drawdown duration | CANC BBC | 16d48d | 80d85d | n/a340d | n/a1822d |
CANC | BBC | |
Last sale 3/13/2026 at 1:30 PM | $35.99 | $40.65 |
| Previous close 03/12/2026 | $36.33 | $41.40 |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
CANC | BBC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
CANC | BBC | |
|---|---|---|
| Last price | $35.99 | $40.65 |
| 1D performance | -0.95% | -1.81% |
| AuM | $161.18 M | $38.68 M |
| E/R | 0.99% | 0.79% |
CANC | BBC | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Tema | VIRTUS Investment Partners |
| Benchmark | - | LifeSci Biotechnology Clinical Trials Index |
| N° of holdings | 46 | 81 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 15, 2023 | December 16, 2014 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
